GSK Says Jemperli Meets Primary Objective in Phase 2 Trial
GSK reported that its cancer drug Jemperli met its primary objective in a phase 2 trial.
Related stories
SoftBank Shares Fall 4% After Quarterly Loss
SoftBank swung to its first quarterly loss in nearly two years, partly due to $3.7 billion in charges tied to power-generation equipment for U.S. data-center projects. Shares fell
M impact | EQUITY | Nov 11, 2026, 02:37 AM UTC
UBS Sees Kalyan Jewellers at ₹900 After Q2 Results
UBS maintained its view after Kalyan Jewellers reported strong September-quarter results and management pointed to healthy festive demand. Net profit rose sharply, aided by an exce
M impact | EQUITY | Nov 11, 2026, 02:36 AM UTC
South Korea’s Kospi Extends Gains, Up 1.2% at 5299.65
M impact | EQUITY | Nov 11, 2026, 02:36 AM UTC
Asian session market picture: S&P 500 +0.48%, Nasdaq 100 +0.97%; USD/JPY +0.08%, WTI +0.57%, 9984 leads volume
Asian session market picture. US index futures: S and P futures is up 0.48 percent, Nasdaq futures is up 0.97 percent, Dow futures is up 0.24 percent and Russell futures is up 0.25
M impact | EQUITY | Nov 11, 2026, 02:30 AM UTC
Alphabet Taps Banks for First HKD and SGD Bond Issue
Alphabet has approached banks about a first bond issue denominated in Hong Kong and Singapore dollars, according to a term sheet.
L impact | EQUITY | Nov 11, 2026, 02:19 AM UTC
Cochin Shipyard Q2 Profitability Weakens as Revenue Grows
Cochin Shipyard reported weak September-quarter results, with profitability declining despite revenue growth. Standalone revenue increased 12.9% year over year.
M impact | EQUITY | Nov 11, 2026, 02:06 AM UTC